CDSCO panel nod to Bajaj Healthcare for Phase III clinical trials of insomnia drug Suvorexant

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-10-04 08:33 GMT | Update On 2025-10-04 08:33 GMT

Mumbai: Bajaj Healthcare Limited has announced that it has received a positive recommendation from the Subject Expert Committee (SEC) (Neurology & Psychiatry) of the Central Drugs Standard Control Organisation (CDSCO) to initiate Phase III clinical trials for Suvorexant Tablets, available in strengths of 5mg, 10mg, 15mg, and 20mg.

Suvorexant is a prescription medication used to treat insomnia in adults. It works by modulating the sleep-wake cycle through the central nervous system, promoting improved sleep onset and maintenance. The upcoming Phase III trials will evaluate the efficacy, safety, and tolerability of Suvorexant in a diverse patient population, representing the final and most crucial step before regulatory submission.

Upon successful completion, Bajaj Healthcare intends to pursue marketing authorization in select markets, paving the way for its commercial launch.

Speaking at the occasion Anil Jain, Managing Director, Bajaj Healthcare Limited, said, “We are encouraged by the SEC’s recommendation and remain committed to advancing Suvorexant through the final stages of clinical development. With our robust R&D infrastructure and GMP-compliant manufacturing capabilities, we are confident in our ability to deliver high-quality, impactful CNS solutions to patients worldwide. This development not only strengthens our neurology portfolio but also aligns with our strategic vision of addressing unmet medical needs in chronic and lifestyle-related disorders.”

Bajaj Healthcare Limited a Manufacturer of APIs, Intermediates and Formulations. Established in the year 1993, it specializes in manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.

Read also: Bajaj Healthcare gets rights to manufacture, distribute, sell Magnesium L Threonate in India

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO panel nod to Bajaj Healthcare for Phase III clinical trials of insomnia drug Suvorexant

Similar News

Syngene International plans to add bioconjugation suite for end-to-end Antibody-Drug conjugates development

CDSCO Panel Rejects Troikaa Pharma's High-Strength Paracetamol Injection Citing Safety Concerns

CDSCO Flags Besto-Cof Cough Syrup as Spurious, Raipur Drug Lab Claims Batch Not Made by Listed Firm

Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide

CDSCO Ends Emergency-Use Authorization of Baricitinib for COVID-19 Treatment

Merck gets USFDA priority review for 2 applications for Keytruda, Keytruda Qlex in combo with Padcev for bladder cancer

CDSCO Flags 112 Drug Batches Including Telmisartan, Pantoprazole, Cefixime, Glimepiride as Not of Standard Quality

Zydus bags Health Canada approval for Mesalamine suppositories for active ulcerative proctitis